Treatment of viral conjunctivitis with antiviral drugs

Drugs

Volumn 71, Issue 3, 2011, Pages 331-347

  Skevaki, Chrysanthi L ^a   Galani, Ioanna E ^b   Pararas, Michail V ^a   Giannopoulou, Konstantina P ^c   Tsakris, Athanassios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^c Athens Eye Hospital   (Greece)

Author keywords

Aciclovir; Cidofovir; Corticosteroids; Famciclovir; Idoxuridine; Infectious conjunctivitis; Trifluridine; Valaciclovir; Viral infections

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ALPHA2 INTERFERON; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; ARTIFICIAL TEAR; BETA INTERFERON; CHLOROTAURINE; CIDOFOVIR; CORTICOSTEROID; CYCLOSPORIN A; DEOXYGLUCOSE; DEXAMETHASONE; FAMCICLOVIR; GENTAMICIN; IDOXURIDINE; INTERFERON; OXIDOREDUCTASE INHIBITOR; PEPTIDOMIMETIC RIBONUCLEOTIDE REDUCTASE INHIBITOR; POVIDONE IODINE; SMALL INTERFERING RNA; STAVUDINE; TAURINE DERIVATIVE; TILORONE; TRIFLURIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIA ANTIBODY; VALACICLOVIR; VIDARABINE; ZALCITABINE;

ACANTHAMOEBA INFECTION; ADENOVIRUS; ADENOVIRUS 19; ADENOVIRUS 3; ADENOVIRUS 37; ADENOVIRUS 4; ADENOVIRUS 8; ADENOVIRUS INFECTION; CONFERENCE PAPER; CONJUNCTIVA DISEASE; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENTEROVIRUS; ENTEROVIRUS 70; ENTEROVIRUS INFECTION; EYELID ERYTHEMA; FELINE HERPES VIRUS 1; HERPES SIMPLEX; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; HERPES VIRUS; HERPES VIRUS INFECTION; HERPES ZOSTER; HERPES ZOSTER OPHTHALMICUS; HUMAN; KERATOCONJUNCTIVITIS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RNA INTERFERENCE; SINGLE DRUG DOSE; STAPHYLOCOCCUS INFECTION; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VACCINIA; VESICULAR STOMATITIS; VIRAL CONJUNCTIVITIS; VIRUS REPLICATION;

ADENOVIRIDAE INFECTIONS; ANIMALS; ANTIVIRAL AGENTS; CONJUNCTIVITIS, VIRAL; HERPESVIRIDAE INFECTIONS; HUMANS; RNA VIRUS INFECTIONS; RNA, SMALL INTERFERING;

HERPESVIRIDAE;

EID: 79951666829     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11585330-000000000-00000     Document Type: Conference Paper

References (81)

1. Cronau H, Kankanala RR, Mauger T. Diagnosis and management of red eye in primary care. Am Fam Physician 2010 Jan 15; 81 (2): 137-44.
2. Kumar NL, Black D, McClellan K. Daytime presentations to a metropolitan ophthalmic emergency department. Clin Experiment Ophthalmol 2005 Dec; 33 (6): 586-92.
3. Weber CM, Eichenbaum JW. Acute red eye: differentiating viral conjunctivitis from other, less common causes. Postgrad Med 1997 May; 101 (5): 185-6, 9-92, 95-6.
4. Chu PY, Ke GM, Chang CH, et al. Molecular epidemiology of coxsackie A type 24 variant in Taiwan, 2000-2007. J Clin Virol 2009 Aug; 45 (4): 285-91.
5. Khan A, Sharif S, Shaukat S, et al. An outbreak of acute hemorrhagic conjunctivitis (AHC) caused by coxsackievirus A24 variant in Pakistan. Virus Res 2008 Oct; 137 (1): 150-2.
6. Madhavan HN, Malathy J, Priya K. An outbreak of acute conjunctivitis caused by Coxsackie virus A 24 [letter]. Indian J Ophthalmol 2000 Jun; 48 (2): 159.
7. Uchio E, Yamazaki K, Ishikawa H, et al. An epidemic of acute haemorrhagic conjunctivitis caused by enterovirus 70 in Okinawa, Japan, in 1994. Graefes Arch Clin Exp Ophthalmol 1999 Jul; 237 (7): 568-72.
8. Tan DS, Yin-Murphy M, Kandiah S. An outbreak of acute conjunctivitis caused by coxsackievirus A24 in Kuala- Lumpur, Malaysia, 1978. Southeast Asian J Trop Med Public Health 1980 Mar; 11 (1): 24-7. (Pubitemid 10007790)
9. Gottsch JD. Surveillance and control of epidemic keratoconjunctivitis. Trans Am Ophthalmol Soc 1996; 94: 539-87. (Pubitemid 26406046)
10. Hamada N, Gotoh K, Hara K, et al. Nosocomial outbreak of epidemic keratoconjunctivitis accompanying environmental contamination with adenoviruses. J Hosp Infect 2008 Mar; 68 (3): 262-8.
11. Kaneko H, Maruko I, Iida T, et al. The possibility of human adenovirus detection from the conjunctiva in asymptomatic cases during nosocomial infection. Cornea 2008 Jun; 27 (5): 527-30.
12. Levandowski RA, Rubenis M. Nosocomial conjunctivitis caused by adenovirus type 4. J Infect Dis 1981 Jan; 143 (1): 28-31. (Pubitemid 11152594)
13. De Clercq E, Neyts J. Antiviral agents acting as DNA or RNA chain terminators. Handb Exp Pharmacol 2009; (189): 53-84.
14. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews andmeta-analyses: the PRISMA statement. PLoS Med 2009 Jul 21; 6 (7): e1000097.
15. Cobo LM, Foulks GN, Liesegang T, et al. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology 1986 Jun; 93 (6): 763-70. (Pubitemid 16068346)
16. Uchoa UB, Rezende RA, Carrasco MA, et al. Long-term acyclovir use to prevent recurrent ocular herpes simplex virus infection. Arch Ophthalmol 2003 Dec; 121 (12): 1702-4. (Pubitemid 37517435)
17. Neoh C, Harding SP, Saunders D, et al. Comparison of topical and oral acyclovir in early herpes zoster ophthalmicus. Eye (Lond) 1994; 8 (Pt 6): 688-91.
18. Goon P, WrightM, Fink C. Ophthalmic zoster sine herpete. J R Soc Med 2000 Apr; 93 (4): 191-2. (Pubitemid 30218871)
19. Parentin F, Molin GD, D'Agaro P, et al. Parinaud's oculoglandular syndrome due to herpes simplex virus type 1. Ocul Immunol Inflamm 2007 Mar-Apr; 15 (2): 139-41. (Pubitemid 46897679)
20. Gajdatsy AD, Kosmin A, Barrett GD. Coexistent adenoviral keratoconjunctivitis and Acanthamoeba keratitis. Clin Experiment Ophthalmol 2000 Dec; 28 (6): 434-6. (Pubitemid 32050931)
21. Gordon YJ, Naesens L, DeClercq E, et al. Treatment of adenoviral conjunctivitis with topical cidofovir [letter]. Cornea 1996 Sep; 15 (5): 546. (Pubitemid 26271797)
22. Castleton A, Kottaridis PD. A case of 'red eye' post allogeneic stem cell transplantation. Bone Marrow Transplant 2007 Feb; 39 (4): 241-2.
23. Hillenkamp J, Reinhard T, Ross RS, et al. Topical treatment of acute adenoviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporine: a controlled clinical pilot study. Arch Ophthalmol 2001 Oct; 119 (10): 1487-91. (Pubitemid 32963253)
24. Hillenkamp J, Reinhard T, Ross RS, et al. The effects of cidofovir 1% with and without cyclosporin A 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study. Ophthalmology 2002 May; 109 (5): 845-50. (Pubitemid 34465214)
25. Tyring S, Engst R, Corriveau C, et al. Famciclovir for ophthalmic zoster: a randomised aciclovir controlled study. Br J Ophthalmol 2001 May; 85 (5): 576-81. (Pubitemid 32397834)
26. Dudgeon J, Bhargava SK, Ross CA. Treatment of adenovirus infection of the eye with 5-iodo-20-deoxyuridine: a double-blind trial. Br J Ophthalmol 1969 Aug; 53 (8): 530-3.
27. Adams Jr CP, Cohen EJ, Albrecht J, et al. Interferon treatment of adenoviral conjunctivitis. Am J Ophthalmol 1984 Oct 15; 98 (4): 429-32. (Pubitemid 14021803)
28. Romano A, Revel M, Guarari-Rotman D, et al. Use of human fibroblast-derived (beta) interferon in the treatment of epidemic adenovirus keratoconjunctivitis. J Interferon Res 1980 Fall; 1 (1): 95-100. (Pubitemid 12108588)
29. Wilhelmus KR, Dunkel EC, Herson J. Topical human fibroblast interferon for acute adenoviral conjunctivitis. Graefes Arch Clin Exp Ophthalmol 1987; 225 (6): 461-4. (Pubitemid 17153723)
30. Hutter H. Epidemic keratoconjunctivitis: treatment results during an epidemic. Klin Monatsbl Augenheilkd 1990 Sep; 197 (3): 214-7.
31. Rossa V, Sundmacher R. Local prevention with interferon of 'epidemic' conjunctivitis caused by a currently unidentifiable virus. Klin Monatsbl Augenheilkd 1991 Sep; 199 (3): 192-4.
32. Romano A, Sadan Y. Ten years of experience with human fibroblast interferon in treatment of viral ophthalmic infections. Metab Pediatr Syst Ophthalmol 1988; 11 (1-2): 43-6.
33. Ward JB, Siojo LG, Waller SG. A prospective, masked clinical trial of trifluridine, dexamethasone, and artificial tears in the treatment of epidemic keratoconjunctivitis. Cornea 1993 May; 12 (3): 216-21. (Pubitemid 23137862)
34. Colin J, Chastel C. Early treatment of ocular herpes simplex: apropos of 6 cases of herpetic conjunctivitis. J Fr Ophtalmol 1985; 8 (12): 801-2. (Pubitemid 16140690)
35. Hu G, Wang MJ,Miller MJ, et al. Ocular vaccinia following exposure to a smallpox vaccinee. Am J Ophthalmol 2004 Mar; 137 (3): 554-6. (Pubitemid 38328649)
36. Fillmore GL, Ward TP, Bower KS, et al. Ocular complications in the Department of Defense Smallpox Vaccination Program. Ophthalmology 2004 Nov; 111 (11): 2086-93. (Pubitemid 39446729)
37. Wander AH. Herpes simplex and recurrent corneal disease. Int Ophthalmol Clin 1984 Summer; 24 (2): 27-38.
38. Zaal MJ, Volker-Dieben HJ, Wienesen M, et al. Longitudinal analysis of varicella-zoster virus DNA on the ocular surface associated with herpes zoster ophthalmicus. Am J Ophthalmol 2001 Jan; 131 (1): 25-9. (Pubitemid 32037004)
39. Colin J, Prisant O, Cochener B, et al. Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus. Ophthalmology 2000 Aug; 107 (8): 1507-11.
40. Teuchner B, Nagl M, Schidlbauer A, et al. Tolerability and efficacy of N-chlorotaurine in epidemic keratoconjunctivitis: a double-blind, randomized, phase-2 clinical trial. J Ocul Pharmacol Ther 2005 Apr; 21 (2): 157-65. (Pubitemid 40577971)
41. Pelletier JS, Stewart K, Trattler W, et al. A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis. Adv Ther 2009 Aug; 26 (8): 776-83.
42. Trousdale MD, Nesburn AB. Evaluation of the antiherpetic activity of acyclovir in rabbits. Am J Med 1982 Jul 20; 73 (1A): 155-60. (Pubitemid 12067776)
43. Romanowski EG, Yates KA, Gordon YJ. Antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5/New Zealand rabbit ocular model. Antiviral Res 2001 Dec; 52 (3): 275-80. (Pubitemid 33000117)
44. Gordon YJ, Romanowski EG, Araullo-Cruz T. Topical HPMPC inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model. Invest Ophthalmol Vis Sci 1994 Nov; 35 (12): 4135-43. (Pubitemid 24350678)
45. Romanowski EG, Araullo-Cruz T, Gordon YJ. Topical corticosteroids reverse the antiviral effect of topical cidofovir in the Ad5-inoculated New Zealand rabbit ocular model. Invest Ophthalmol Vis Sci 1997 Jan; 38 (1): 253-7. (Pubitemid 27051544)
46. Romanowski EG, Gordon YJ, Araullo-Cruz T, et al. The antiviral resistance and replication of cidofovir-resistant adenovirus variants in the New ZealandWhite rabbit ocular model. Invest Ophthalmol Vis Sci 2001 Jul; 42 (8): 1812-5. (Pubitemid 32652357)
47. Kaneko H, Mori S, Suzuki O, et al. The cotton rat model for adenovirus ocular infection: antiviral activity of cidofovir. Antiviral Res 2004 Jan; 61 (1): 63-6. (Pubitemid 37506092)
48. Fontenelle JP, Powell CC, Veir JK, et al. Effect of topical ophthalmic application of cidofovir on experimentally induced primary ocular feline herpesvirus-1 infection in cats. Am J Vet Res 2008 Feb; 69 (2): 289-93. (Pubitemid 351278698)
49. Inoue H, Sonoda KH, IshikawaM, et al. Clinical evaluation of local ocular toxicity in candidate anti-adenoviral agents in vivo. Ophthalmologica 2009; 223 (4): 233-8.
50. Malik R, Lessels NS, Webb S, et al. Treatment of feline herpesvirus-1 associated disease in cats with famciclovir and related drugs. J Feline Med Surg 2009 Jan; 11 (1): 40-8.
51. Tokumaru T. The mode of inhibition of herpes simplex and vesicular stomatitis ocular viral infections in the rabbit and hamster by an interferon inducer tilorone dihydrochloride. Res Commun Chem Pathol Pharmacol 1975 Jun; 11 (2): 289-301.
52. Bitko V, Musiyenko A, Barik S. Viral infection of the lungs through the eye. J Virol 2007 Jan; 81 (2): 783-90. (Pubitemid 46067904)
53. Stiles J. Treatment of cats with ocular disease attributable to herpesvirus infection: 17 cases (1983-1993). J Am Vet Med Assoc 1995 Sep 1; 207 (5): 599-603.
54. Mohanty SB, Rockemann DD, Tripathy RN. Chemotherapeutic value of 2-deoxy-D-glucose in infectious bovine rhinotracheitis viral infection in calves. Am J Vet Res 1980 Jul; 41 (7): 1049-51. (Pubitemid 11247871)
55. Brandt CR, Spencer B, Imesch P, et al. Evaluation of a peptidomimetic ribonucleotide reductase inhibitor with a murine model of herpes simplex virus type 1 ocular disease. Antimicrob Agents Chemother 1996 May; 40 (5): 1078-84. (Pubitemid 26141394)
56. Epstein SP, Pashinsky YY, Gershon D, et al. Efficacy of topical cobalt chelate CTC-96 against adenovirus in a cell culture model and against adenovirus keratoconjunctivitis in a rabbit model. BMC Ophthalmol 2006; 6: 22.
57. Trousdale MD, Goldschmidt PL, Nobrega R. Activity of ganciclovir against human adenovirus type-5 infection in cell culture and cotton rat eyes. Cornea 1994 Sep; 13 (5): 435-9. (Pubitemid 24260318)
58. Romanowski EG, Yates KA, Gordon YJ. The in vitro and in vivo evaluation of ddC as a topical antiviral for ocular adenovirus infections. Invest Ophthalmol Vis Sci 2009 Nov; 50 (11): 5295-9.
59. Gordon YJ,Romanowski E,Araullo-Cruz T, et al. Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 20-nor-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro. Antiviral Res 1991 Jul; 16 (1): 11-6.
60. Langford MP, Kadi RM, Ganley JP, et al. Inhibition of epidemic isolates of coxsackievirus type A 24 by recombinant and natural interferon alpha and interferon beta. Intervirology 1988; 29 (6): 320-7.
61. Langford MP, Orillac R, Chen D, et al. Systemic and ocular antibody responses to inactivated acute hemorrhagic conjunctivitis (AHC) virus; enterovirus 70 (EV70). Ocul Immunol Inflamm 2003 Sep; 11 (3): 197-209. (Pubitemid 37500198)
62. Langford MP, Villarreal AL, Stanton GJ. Antibody and interferon act synergistically to inhibit enterovirus, adenovirus, and herpes simplex virus infection. Infect Immun 1983 Jul; 41 (1): 214-8. (Pubitemid 13063041)
63. Jun EJ, Nam YR, Ahn J, et al. Antiviral potency of a siRNA targeting a conserved region of coxsackievirus A24. Biochem Biophys Res Commun 2008 Nov 14; 376 (2): 389-94.
64. Jun EJ, Won MA, Ahn J, et al. An antiviral small-interfering RNA simultaneously effective against the most prevalent enteroviruses causing acute hemorrhagic conjunctivitis. Invest Ophthalmol Vis Sci 2011; 52 (1): 58-63.
65. Tan EL, Marcus KF, Poh CL. Development of RNA interference (RNAi) as potential antiviral strategy against enterovirus 70. J Med Virol 2008 Jun; 80 (6): 1025-32. (Pubitemid 351657015)
66. Monnerat N, Bossart W, Thiel MA. Povidone-iodine for treatment of adenoviral conjunctivitis: an in vitro study. Klin Monatsbl Augenheilkd 2006 May; 223 (5): 349-52. (Pubitemid 44194844)
67. Uchio E, Fuchigami A, Kadonosono K, et al. Anti-adenoviral effect of anti-HIV agents in vitro in serotypes inducing keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol 2007 Sep; 245 (9): 1319-25. (Pubitemid 47278669)
68. Langford MP, Carr DJ, Yin-Murphy M. Activity of arildone with or without interferon against acute hemorrhagic conjunctivitis viruses in cell culture. Antimicrob Agents Chemother 1985 Oct; 28 (4): 578-80. (Pubitemid 16236554)
69. Langford MP, Ball WA, Ganley JP. Inhibition of the enteroviruses that cause acute hemorrhagic conjunctivitis (AHC) by benzimidazoles; enviroxime (LY 122772) and enviradone (LY 127123). Antiviral Res 1995 Aug; 27 (4): 355-65.
70. Johansson SM, Nilsson EC, Elofsson M, et al. Multivalent sialic acid conjugates inhibit adenovirus type 37 from binding to and infecting human corneal epithelial cells. Antiviral Res 2007 Feb; 73 (2): 92-100. (Pubitemid 46135767)
71. Stuart-Harris C. The epidemiology and clinical presentation of herpes virus infections. J Antimicrob Chemother 1983 Sep; 12 Suppl. B: 1-8.
72. Kaufman HE, Nesburn AB, Maloney ED. Cure of vaccinia infection by 5-iodo-20-deoxyuridine. Virology 1962 Dec; 18: 567-9.
73. Angra SK. IDU ocular toxicity. Indian J Ophthalmol 1977 Jul; 25 (2): 38-41.
74. Romanowski EG, Roba LA, Wiley L, et al. The effects of corticosteroids of adenoviral replication. Arch Ophthalmol 1996 May; 114 (5): 581-5.
75. Romanowski EG, Yates KA, Gordon YJ. Short-term treatment with a potent topical corticosteroid of an acute ocular adenoviral infection in the New Zealand white rabbit. Cornea 2001 Aug; 20 (6): 657-60. (Pubitemid 32706206)
76. Gordon YJ, Araullo-Cruz T, Romanowski EG. The effects of topical nonsteroidal anti-inflammatory drugs on adenoviral replication. Arch Ophthalmol 1998 Jul; 116 (7): 900-5. (Pubitemid 28554780)
77. Dawson CR, Togni B. Herpes simplex eye infections: clinical manifestations, pathogenesis and management. Surv Ophthalmol 1976 Sep-Oct; 21 (2): 121-35.
78. Two fatal cases of adenovirus-related illness in previously healthy young adults: Illinois, 2000.MMWRMorb Mortal Wkly Rep 2001 Jul 6; 50 (26): 553-5.
79. O'Brien V. Viruses and apoptosis. J Gen Virol 1998 Aug; 79 (Pt 8): 1833-45. (Pubitemid 28392266)
80. Curreli F, Friedman-Kien AE, Flore O. Glycyrrhizic acid alters Kaposi sarcoma-associated herpesvirus latency, triggering p53-mediated apoptosis in transformed B lymphocytes. J Clin Invest 2005 Mar; 115 (3): 642-52. (Pubitemid 40322238)
81. Young RC, Hodge DO, Liesegang TJ, et al. Incidence, recurrence, and outcomes of herpes simplex virus eye disease in Olmsted County, Minnesota, 1976-2007: the effect of oral antiviral prophylaxis. Arch Ophthalmol 2010 Sep; 128 (9): 1178-83